Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:18:46.106Z.
Calculation as of: 2026-10-06T21:18:46.106Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 42c577abd9d5aa4e94c21ca47db030ff1e5598993d2f9cb9fa7ffb886cc2a8f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Xenetic Biosciences, Inc.
Market Cap
$4.86M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | $4.86M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.69M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.53M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
